Faster, more efficient oncology clinical trials
Exactis has strong research relationships with a broad range of pharmaceutical and biotech companies developing new precision cancer therapies, allowing it to complete the connection among potential study sponsors, cancer treatment centres and Canadian patients.
The innovative Exactis research network (consortium) meets a growing need of biopharmaceutical drug developers to study new precision treatments in rare populations of patients with very specific molecular profiles in their cancer. Offering study sponsors faster and simpler patient enrolment for rarer cancer populations encourages clinical studies in Canada.
Learn more about PMT